View in EDS HTML Full Text PDF Full Text

Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.

Saved in:
Bibliographic Details
Title: Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.
Authors: Azevedo RS; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Braish J; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gener-Ricos G; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tang G; Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sasaki K; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Montalban-Bravo G; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jabbour E; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ohanian M; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yilmaz M; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Haddad FG; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chien K; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ishizawa J; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Short NJ; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Maiti A; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Swaminathan M; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian H; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia TM; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Source: Leukemia & lymphoma [Leuk Lymphoma] 2026 Jan; Vol. 67 (1), pp. 220-224. Date of Electronic Publication: 2025 Oct 31.
Publication Type: Journal Article
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41173347
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Azevedo+RS%22">Azevedo RS</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Braish+J%22">Braish J</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Gener-Ricos+G%22">Gener-Ricos G</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Tang+G%22">Tang G</searchLink>; Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Sasaki+K%22">Sasaki K</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Montalban-Bravo+G%22">Montalban-Bravo G</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Jabbour+E%22">Jabbour E</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Ohanian+M%22">Ohanian M</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Yilmaz+M%22">Yilmaz M</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Haddad+FG%22">Haddad FG</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Chien+K%22">Chien K</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Ishizawa+J%22">Ishizawa J</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Short+NJ%22">Short NJ</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Maiti+A%22">Maiti A</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Swaminathan+M%22">Swaminathan M</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Kantarjian+H%22">Kantarjian H</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Borthakur+G%22">Borthakur G</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Kadia+TM%22">Kadia TM</searchLink>; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007422%22">Leukemia & lymphoma</searchLink> [Leuk Lymphoma] 2026 Jan; Vol. 67 (1), pp. 220-224. <i>Date of Electronic Publication: </i>2025 Oct 31.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9007422 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1029-2403 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210268022%22">10268022 </searchLink><i>NLM ISO Abbreviation: </i>Leuk Lymphoma <i>Subsets: </i>MEDLINE; In Process
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41173347
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/10428194.2025.2568745
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 220
    Titles:
      – TitleFull: Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Azevedo RS
      – PersonEntity:
          Name:
            NameFull: Braish J
      – PersonEntity:
          Name:
            NameFull: Gener-Ricos G
      – PersonEntity:
          Name:
            NameFull: Tang G
      – PersonEntity:
          Name:
            NameFull: Sasaki K
      – PersonEntity:
          Name:
            NameFull: Montalban-Bravo G
      – PersonEntity:
          Name:
            NameFull: Jabbour E
      – PersonEntity:
          Name:
            NameFull: Ohanian M
      – PersonEntity:
          Name:
            NameFull: Yilmaz M
      – PersonEntity:
          Name:
            NameFull: Haddad FG
      – PersonEntity:
          Name:
            NameFull: Chien K
      – PersonEntity:
          Name:
            NameFull: Ishizawa J
      – PersonEntity:
          Name:
            NameFull: Short NJ
      – PersonEntity:
          Name:
            NameFull: Maiti A
      – PersonEntity:
          Name:
            NameFull: Swaminathan M
      – PersonEntity:
          Name:
            NameFull: Kantarjian H
      – PersonEntity:
          Name:
            NameFull: Borthakur G
      – PersonEntity:
          Name:
            NameFull: Kadia TM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2026 Jan
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1029-2403
          Numbering:
            – Type: volume
              Value: 67
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Leukemia & lymphoma
              Type: main
ResultId 1